Shandong Xinhua Pharmaceutical Co (HKSE:00719) Change In Receivables : HK$0 Mil (TTM As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Shandong Xinhua Pharmaceutical Co Change In Receivables?

Shandong Xinhua Pharmaceutical Co's change in receivables for the quarter that ended in Mar. 2024 was HK$0 Mil. It means Shandong Xinhua Pharmaceutical Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Shandong Xinhua Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2023 was HK$-463 Mil. It means Shandong Xinhua Pharmaceutical Co's Accounts Receivable increased by HK$463 Mil from Dec. 2022 to Dec. 2023 .

Shandong Xinhua Pharmaceutical Co's Accounts Receivable for the quarter that ended in Mar. 2024 was HK$1,151 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Shandong Xinhua Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 39.07.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Shandong Xinhua Pharmaceutical Co's liquidation value for the three months ended in Mar. 2024 was HK$-1,297 Mil.

Shandong Xinhua Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Shandong Xinhua Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Xinhua Pharmaceutical Co Change In Receivables Chart

Shandong Xinhua Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-335.01

-810.02

-919.67

-801.05

-463.26

Shandong Xinhua Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Shandong Xinhua Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Shandong Xinhua Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1151.028	/	2688.267	*	91
=	39.07

2. In Ben Graham's calculation of liquidation value, Shandong Xinhua Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Shandong Xinhua Pharmaceutical Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1001.629	-	3777.089	+	0.75 * 1151.028	+	0.5 * 1230.922
=	-1,297

Shandong Xinhua Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Shandong Xinhua Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) » Definitions » Change In Receivables

Traded in Other Exchanges

XIN:Germany 000756:China

Address

No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo City, Shandong, CHN, 255086

Website

http://www.xhzy.com

Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Headlines

No Headlines